InMed Pharmaceuticals (INM) Stock Price, News & Analysis

Company Overview

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company's lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.

Key Stats

• Today's Range: $3.08 to $3.39
• 50-Day Range: $3.07 to $5.19
• 52-Week Range: $2.41 to $15.70
• Volume: 36,194 shs
• Average Volume: 82,280 shs
• Market Capitalization: $3.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

InMed Pharmaceuticals Stock Analysis - MarketRank™

InMed Pharmaceuticals scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for InMed Pharmaceuticals.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of InMed Pharmaceuticals is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of InMed Pharmaceuticals is -0.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

InMed Pharmaceuticals has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.74% of the outstanding shares of InMed Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InMed Pharmaceuticals has recently increased by 1,125.93%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

InMed Pharmaceuticals does not currently pay a dividend.

Dividend Growth

InMed Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.74% of the outstanding shares of InMed Pharmaceuticals have been sold short.

Short Interest Ratio / Days to Cover

InMed Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in InMed Pharmaceuticals has recently increased by 1,125.93%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

1 people have searched for INM on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added InMed Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, InMed Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.85% of the stock of InMed Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 20.12% of the stock of InMed Pharmaceuticals is held by institutions.

INM Stock Analysis - Frequently Asked Questions

How have INM shares performed this year?

InMed Pharmaceuticals' stock was trading at $4.74 on January 1st, 2025. Since then, INM shares have decreased by 34.2% and is now trading at $3.12.
View the best growth stocks for 2025 here.

How were InMed Pharmaceuticals' earnings last quarter?

InMed Pharmaceuticals Inc. (NASDAQ:INM) released its earnings results on Wednesday, February, 12th. The company reported ($3.64) earnings per share (EPS) for the quarter. InMed Pharmaceuticals had a negative net margin of 163.75% and a negative trailing twelve-month return on equity of 90.74%.

When did InMed Pharmaceuticals' stock split?

InMed Pharmaceuticals's stock reverse split on the morning of Wednesday, September 7th 2022. The 1-25 reverse split was announced on Wednesday, September 7th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 7th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Who are InMed Pharmaceuticals' major shareholders?

Top institutional investors of InMed Pharmaceuticals include AdvisorShares Investments LLC (5.34%). Insiders that own company stock include Eric A Adams and Andrew Hull.
View institutional ownership trends.

How do I buy shares of InMed Pharmaceuticals?

Shares of INM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of InMed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that InMed Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Broadcom (AVGO), Tesla (TSLA) and PayPal (PYPL).

Company Calendar

• Last Earnings: 2/12/2025
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:INM
• CUSIP: N/A
• CIK: 1728328
• Web: www.inmedpharma.com
• Phone: 604-669-7207
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($13.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,680,000.00
• Net Margins: -163.75%
• Pretax Margin: -163.58%
• Return on Equity: -90.74%
• Return on Assets: -71.70%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 3.05
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $4.60 million
• Price / Sales: 0.82
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.12 per share
• Price / Book: 0.61

Miscellaneous

• Outstanding Shares: 1,210,000
• Free Float: 711,000
• Market Cap: $3.78 million
• Optionable: Not Optionable
• Beta: 0.19